;PMID: 11719439
;source_file_704.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..117] = [t:43..117]
;2)section:[e:121..256] = [t:121..256]
;3)section:[e:260..357] = [t:260..357]
;4)sentence:[e:361..544] = [t:361..544]
;5)sentence:[e:545..695] = [t:545..695]
;6)sentence:[e:696..871] = [t:696..871]
;7)sentence:[e:872..938] = [t:872..938]
;8)sentence:[e:939..1046] = [t:939..1046]
;9)sentence:[e:1047..1182] = [t:1047..1182]
;10)sentence:[e:1183..1354] = [t:1183..1354]
;11)sentence:[e:1355..1573] = [t:1355..1573]
;12)sentence:[e:1574..1742] = [t:1574..1742]
;13)section:[e:1746..1791] = [t:1746..1791]

;section 0 Span:0..38
;Cancer Res  2001 Nov 15;61(22):8118-21
(SEC
  (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 2001)
        (IN:[17..20] Nov) ($:[21..27] 15;61-LRB-) (CD:[27..29] 22)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :8118) (::[35..36] -)
        (CD:[36..38] 21)))

;sentence 1 Span:43..117
;KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
;[43..46]:gene-rna:"KIT"
;[85..116]:malignancy:"gastrointestinal stromal tumors"
(SENT
  (S
    (NP-SBJ (NN:[43..46] KIT) (NN:[47..57] activation))
    (VP (VBZ:[58..60] is)
      (NP-PRD
        (NP (DT:[61..62] a) (JJ:[63..73] ubiquitous) (NN:[74..81] feature))
        (PP (IN:[82..84] of)
          (NP (JJ:[85..101] gastrointestinal) (JJ:[102..109] stromal)
              (NNS:[110..116] tumors)))))
    (.:[116..117] .)))

;section 2 Span:121..256
;Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, 
;Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA.
(SEC
  (FRAG (NNP:[121..126] Rubin) (NNP:[127..129] BP) (,:[129..130] ,)
        (NNP:[131..137] Singer) (NNP:[138..140] S,) (NNP:[141..145] Tsao)
        (NNP:[146..147] C) (,:[147..148] ,) (NNP:[149..157] Duensing)
        (NNP:[158..159] A) (,:[159..160] ,) (NNP:[161..164] Lux)
        (NNP:[165..167] ML) (,:[167..168] ,) (NNP:[169..173] Ruiz)
        (NNP:[174..176] R,) (NNP:[177..184] Hibbard) (NNP:[185..187] MK)
        (,:[187..188] ,) (NNP:[189..193] Chen) (NNP:[194..196] CJ)
        (,:[196..197] ,) (NNP:[199..203] Xiao) (NNP:[204..206] S,)
        (NNP:[207..214] Tuveson) (NNP:[215..217] DA) (,:[217..218] ,)
        (NNP:[219..226] Demetri) (NNP:[227..229] GD) (,:[229..230] ,)
        (NNP:[231..239] Fletcher) (NNP:[240..242] CD) (,:[242..243] ,)
        (NNP:[244..252] Fletcher) (NNP:[253..256] JA.)))

;section 3 Span:260..357
;Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, 
;Boston, MA 02115, USA.
(SEC
  (FRAG (NNP:[260..270] Department) (IN:[271..273] of)
        (NNP:[274..283] Pathology) (,:[283..284] ,) (NNP:[285..292] Brigham)
        (CC:[293..296] and) (NNP:[297..302] Women) (POS:[302..304] 's)
        (NNP:[305..313] Hospital) (,:[313..314] ,) (VBZ:[315..317] 75)
        (NNP:[318..325] Francis) (NNP:[326..332] Street) (,:[332..333] ,)
        (NNP:[335..341] Boston) (,:[341..342] ,) (NNP:[343..345] MA)
        (CD:[346..351] 02115) (,:[351..352] ,) (NNP:[353..356] USA)
        (.:[356..357] .)))

;sentence 4 Span:361..544
;Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal
;tumors  of the gastrointestinal tract, and they are generally resistant to
;chemotherapy  and radiation therapy.
;[361..392]:malignancy:"Gastrointestinal stromal tumors"
;[394..399]:malignancy:"GISTs"
;[421..470]:malignancy:"mesenchymal tumors  of the gastrointestinal tract"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (JJ:[361..377] Gastrointestinal) (JJ:[378..385] stromal)
            (NNS:[386..392] tumors))
        (NP (-LRB-:[393..394] -LRB-) (NNS:[394..399] GISTs)
            (-RRB-:[399..400] -RRB-)))
      (VP (VBP:[401..404] are)
        (NP-PRD
          (NP (DT:[405..408] the)
            (ADJP (RBS:[409..413] most) (JJ:[414..420] common))
            (JJ:[421..432] mesenchymal) (NNS:[433..439] tumors))
          (PP (IN:[441..443] of)
            (NP (DT:[444..447] the) (JJ:[448..464] gastrointestinal)
                (NN:[465..470] tract))))))
    (,:[470..471] ,) (CC:[472..475] and)
    (S
      (NP-SBJ (PRP:[476..480] they))
      (VP (VBP:[481..484] are)
        (ADVP (RB:[485..494] generally))
        (ADJP-PRD (JJ:[495..504] resistant)
          (PP (TO:[505..507] to)
            (NP
              (NP (NN:[508..520] chemotherapy))
              (CC:[522..525] and)
              (NP (NN:[526..535] radiation) (NN:[536..543] therapy)))))))
    (.:[543..544] .)))

;sentence 5 Span:545..695
;Most GISTs express the KIT receptor tyrosine kinase  protein, and a subset of
;GISTs contain activating mutations within the KIT  juxtamembrane region.
;[550..555]:malignancy:"GISTs"
;[568..596]:gene-protein:"KIT receptor tyrosine kinase"
;[623..628]:malignancy:"GISTs"
;[669..672]:gene-rna:"KIT"
(SENT
  (S
    (S
      (NP-SBJ (DT:[545..549] Most) (NNS:[550..555] GISTs))
      (VP (VBP:[556..563] express)
        (NP (DT:[564..567] the)
          (NML (NN:[568..571] KIT) (NN:[572..580] receptor)
               (NN:[581..589] tyrosine) (NN:[590..596] kinase))
          (NN:[598..605] protein))))
    (,:[605..606] ,) (CC:[607..610] and)
    (S
      (NP-SBJ
        (NP (DT:[611..612] a) (NN:[613..619] subset))
        (PP (IN:[620..622] of)
          (NP (NNS:[623..628] GISTs))))
      (VP (VBP:[629..636] contain)
        (NP
          (NP (VBG:[637..647] activating) (NNS:[648..657] mutations))
          (PP-LOC (IN:[658..664] within)
            (NP (DT:[665..668] the) (NN:[669..672] KIT)
                (NN:[674..687] juxtamembrane) (NN:[688..694] region))))))
    (.:[694..695] .)))

;sentence 6 Span:696..871
;We evaluated 48 GISTs, including 10 benign, 10 borderline,  and 28 malignant
;cases, to determine whether KIT expression and activation are  general
;properties of these tumors.
;[712..717]:malignancy:"GISTs"
;[732..738]:malignancy:"benign"
;[743..753]:malignancy:"borderline"
;[763..772]:malignancy:"malignant"
;[801..804]:gene-generic:"KIT"
;[864..870]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ (PRP:[696..698] We))
    (VP (VBD:[699..708] evaluated)
      (NP
        (NP (CD:[709..711] 48) (NNS:[712..717] GISTs))
        (,:[717..718] ,)
        (PP (VBG:[719..728] including)
          (NP
            (NP (CD:[729..731] 10) (JJ:[732..738] benign)
              (NML-1 (-NONE-:[738..738] *P*)))
            (,:[738..739] ,)
            (NP (CD:[740..742] 10) (JJ:[743..753] borderline)
              (NML-1 (-NONE-:[753..753] *P*)))
            (,:[753..754] ,) (CC:[756..759] and)
            (NP (CD:[760..762] 28) (JJ:[763..772] malignant)
              (NML-1 (NNS:[773..778] cases))))))
      (,:[778..779] ,)
      (S-PRP
        (NP-SBJ (-NONE-:[779..779] *))
        (VP (TO:[780..782] to)
          (VP (VB:[783..792] determine)
            (SBAR (IN:[793..800] whether)
              (S
                (NP-SBJ
                  (NP (NN:[801..804] KIT) (NN:[805..815] expression))
                  (CC:[816..819] and)
                  (NP (NN:[820..830] activation)))
                (VP (VBP:[831..834] are)
                  (NP-PRD
                    (NP (JJ:[836..843] general) (NNS:[844..854] properties))
                    (PP (IN:[855..857] of)
                      (NP (DT:[858..863] these) (NNS:[864..870] tumors)))))))))))
    (.:[870..871] .)))

;sentence 7 Span:872..938
;Immunohistochemical KIT expression was  demonstrated in each case.
;[892..895]:gene-protein:"KIT"
(SENT
  (S
    (NP-SBJ-1 (JJ:[872..891] Immunohistochemical) (NN:[892..895] KIT)
              (NN:[896..906] expression))
    (VP (VBD:[907..910] was)
      (VP (VBN:[912..924] demonstrated)
        (NP-1 (-NONE-:[924..924] *))
        (PP (IN:[925..927] in)
          (NP (DT:[928..932] each) (NN:[933..937] case)))))
    (.:[937..938] .)))

;sentence 8 Span:939..1046
;Somatic KIT mutations were found in 44 tumors (92%),  of which 34 (71%) had
;juxtamembrane region mutations.
;[947..950]:gene-rna:"KIT"
;[978..984]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ-1 (JJ:[939..946] Somatic) (NN:[947..950] KIT)
              (NNS:[951..960] mutations))
    (VP (VBD:[961..965] were)
      (VP (VBN:[966..971] found)
        (NP-1 (-NONE-:[971..971] *))
        (PP-LOC (IN:[972..974] in)
          (NP
            (NP (CD:[975..977] 44) (NNS:[978..984] tumors)
              (PRN (-LRB-:[985..986] -LRB-)
                (NP (CD:[986..988] 92) (NN:[988..989] %))
                (-RRB-:[989..990] -RRB-)))
            (,:[990..991] ,)
            (SBAR
              (WHPP (IN:[993..995] of)
                (WHNP (WDT:[996..1001] which)))
              (S
                (NP-SBJ
                  (NP (CD:[1002..1004] 34)
                    (PRN (-LRB-:[1005..1006] -LRB-)
                      (NP (CD:[1006..1008] 71) (NN:[1008..1009] %))
                      (-RRB-:[1009..1010] -RRB-)))
                  (PP (-NONE-:[1010..1010] *T*)))
                (VP (VBD:[1011..1014] had)
                  (NP
                    (NML (NN:[1015..1028] juxtamembrane)
                         (NN:[1029..1035] region))
                    (NN:[1036..1045] mutations)))))))))
    (.:[1045..1046] .)))

;sentence 9 Span:1047..1182
;Other GISTs had KIT  mutations in the extracellular region (n = 6) and in two
;different regions in  the tyrosine kinase domain (n = 4).
;[1053..1058]:malignancy:"GISTs"
;[1063..1066]:gene-rna:"KIT"
;[1151..1166]:gene-protein:"tyrosine kinase"
(SENT
  (S
    (NP-SBJ (JJ:[1047..1052] Other) (NNS:[1053..1058] GISTs))
    (VP (VBD:[1059..1062] had)
      (NP (NN:[1063..1066] KIT) (NNS:[1068..1077] mutations))
      (PP-LOC
        (PP (IN:[1078..1080] in)
          (NP (DT:[1081..1084] the) (JJ:[1085..1098] extracellular)
              (NN:[1099..1105] region)
            (PRN (-LRB-:[1106..1107] -LRB-)
              (S
                (NP-SBJ (NN:[1107..1108] n))
                (VP (SYM:[1109..1110] =)
                  (NP (CD:[1111..1112] 6))))
              (-RRB-:[1112..1113] -RRB-))))
        (CC:[1114..1117] and)
        (PP (IN:[1118..1120] in)
          (NP
            (NP (CD:[1121..1124] two) (JJ:[1125..1134] different)
                (NNS:[1135..1142] regions))
            (PP (IN:[1143..1145] in)
              (NP (DT:[1147..1150] the)
                (NML (NN:[1151..1159] tyrosine) (NN:[1160..1166] kinase))
                (NN:[1167..1173] domain)))
            (PRN (-LRB-:[1174..1175] -LRB-)
              (S
                (NP-SBJ (NN:[1175..1176] n))
                (VP (SYM:[1177..1178] =)
                  (NP (CD:[1179..1180] 4))))
              (-RRB-:[1180..1181] -RRB-))))))
    (.:[1181..1182] .)))

;sentence 10 Span:1183..1354
;Contrary to previous reports, KIT mutations  were not identified
;preferentially in higher-grade tumors: indeed, they were  found in each of 10
;histologically benign GISTs.
;[1213..1216]:gene-rna:"KIT"
;[1266..1285]:malignancy:"higher-grade tumors"
;[1341..1353]:malignancy:"benign GISTs"
(SENT
  (S
    (S
      (S-ADV
        (NP-SBJ (-NONE-:[1183..1183] *))
        (ADJP-PRD (JJ:[1183..1191] Contrary)
          (PP (TO:[1192..1194] to)
            (NP (JJ:[1195..1203] previous) (NNS:[1204..1211] reports)))))
      (,:[1211..1212] ,)
      (NP-SBJ-1 (NN:[1213..1216] KIT) (NNS:[1217..1226] mutations))
      (VP (VBD:[1228..1232] were) (RB:[1233..1236] not)
        (VP (VBN:[1237..1247] identified)
          (NP-1 (-NONE-:[1247..1247] *))
          (ADVP (RB:[1248..1262] preferentially))
          (PP (IN:[1263..1265] in)
            (NP
              (NML (JJR:[1266..1272] higher) (HYPH:[1272..1273] -)
                   (NN:[1273..1278] grade))
              (NNS:[1279..1285] tumors))))))
    (::[1285..1286] :)
    (S
      (ADVP (RB:[1287..1293] indeed))
      (,:[1293..1294] ,)
      (NP-SBJ-2 (PRP:[1295..1299] they))
      (VP (VBD:[1300..1304] were)
        (VP (VBN:[1306..1311] found)
          (NP-2 (-NONE-:[1311..1311] *))
          (PP-LOC (IN:[1312..1314] in)
            (NP
              (NP (DT:[1315..1319] each))
              (PP (IN:[1320..1322] of)
                (NP (CD:[1323..1325] 10)
                  (ADJP (RB:[1326..1340] histologically)
                        (JJ:[1341..1347] benign))
                  (NNS:[1348..1353] GISTs))))))))
    (.:[1353..1354] .)))

;sentence 11 Span:1355..1573
;Notably, mutations in all KIT  domains were associated with high-level KIT
;activation/phosphorylation, and KIT  activation was also demonstrated in the
;four GISTs that lacked detectable KIT  genomic and cDNA mutations.
;[1381..1384]:gene-rna:"KIT"
;[1426..1429]:gene-generic:"KIT"
;[1462..1465]:gene-rna:"KIT"
;[1512..1517]:malignancy:"GISTs"
;[1541..1544]:gene-rna:"KIT"
(SENT
  (S
    (S
      (ADVP (RB:[1355..1362] Notably))
      (,:[1362..1363] ,)
      (NP-SBJ-1
        (NP (NNS:[1364..1373] mutations))
        (PP-LOC (IN:[1374..1376] in)
          (NP (DT:[1377..1380] all) (NN:[1381..1384] KIT)
              (NNS:[1386..1393] domains))))
      (VP (VBD:[1394..1398] were)
        (VP (VBN:[1399..1409] associated)
          (NP-1 (-NONE-:[1409..1409] *))
          (PP-CLR (IN:[1410..1414] with)
            (NP
              (NML (JJ:[1415..1419] high) (HYPH:[1419..1420] -)
                   (NN:[1420..1425] level))
              (NN:[1426..1429] KIT) (NN:[1430..1440] activation)
               (SYM:[1440..1441] /) (NN:[1441..1456] phosphorylation))))))
    (,:[1456..1457] ,) (CC:[1458..1461] and)
    (S
      (NP-2 (NN:[1462..1465] KIT) (NN:[1467..1477] activation))
      (VP (VBD:[1478..1481] was)
        (ADVP (RB:[1482..1486] also))
        (VP (VBN:[1487..1499] demonstrated)
          (NP-2 (-NONE-:[1499..1499] *T*))
          (PP-LOC (IN:[1500..1502] in)
            (NP
              (NP (DT:[1503..1506] the) (CD:[1507..1511] four)
                  (NNS:[1512..1517] GISTs))
              (SBAR
                (WHNP-6 (WDT:[1518..1522] that))
                (S
                  (NP-SBJ-6 (-NONE-:[1522..1522] *T*))
                  (VP (VBD:[1523..1529] lacked)
                    (NP
                      (NP
                        (ADJP-5 (JJ:[1530..1540] detectable))
                        (NML-4 (NN:[1541..1544] KIT))
                        (JJ:[1546..1553] genomic)
                        (NML-3 (-NONE-:[1553..1553] *P*)))
                      (CC:[1554..1557] and)
                      (NP
                        (ADJP-5 (-NONE-:[1557..1557] *P*))
                        (NML-4 (-NONE-:[1557..1557] *P*))
                        (NN:[1558..1562] cDNA)
                        (NML-3 (NNS:[1563..1572] mutations))))))))))))
    (.:[1572..1573] .)))

;sentence 12 Span:1574..1742
;These studies underscore the role of KIT activation  in GIST pathogenesis,
;and they suggest that activated KIT might represent a  universal therapeutic
;target in GISTs.
;[1611..1614]:gene-rna:"KIT"
;[1630..1634]:malignancy:"GIST"
;[1681..1684]:gene-rna:"KIT"
;[1736..1741]:malignancy:"GISTs"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1574..1579] These) (NNS:[1580..1587] studies))
      (VP (VBP:[1588..1598] underscore)
        (NP
          (NP (DT:[1599..1602] the) (NN:[1603..1607] role))
          (PP (IN:[1608..1610] of)
            (NP (NN:[1611..1614] KIT) (NN:[1615..1625] activation)))
          (PP (IN:[1627..1629] in)
            (NP (NN:[1630..1634] GIST) (NN:[1635..1647] pathogenesis))))))
    (,:[1647..1648] ,) (CC:[1649..1652] and)
    (S
      (NP-SBJ (PRP:[1653..1657] they))
      (VP (VBP:[1658..1665] suggest)
        (SBAR (IN:[1666..1670] that)
          (S
            (NP-SBJ (VBN:[1671..1680] activated) (NN:[1681..1684] KIT))
            (VP (MD:[1685..1690] might)
              (VP (VB:[1691..1700] represent)
                (NP (DT:[1701..1702] a) (JJ:[1704..1713] universal)
                    (JJ:[1714..1725] therapeutic) (NN:[1726..1732] target))
                (PP-LOC (IN:[1733..1735] in)
                  (NP (NNS:[1736..1741] GISTs)))))))))
    (.:[1741..1742] .)))

;section 13 Span:1746..1791
;PMID: 11719439 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1746..1750] PMID) (::[1750..1751] :) (CD:[1752..1760] 11719439)
        (NN:[1761..1762] -LSB-) (NNP:[1762..1768] PubMed) (::[1769..1770] -)
        (NN:[1771..1778] indexed) (IN:[1779..1782] for)
        (NNP:[1783..1791] MEDLINE-RSB-)))
